

# Vamshi K Rao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2456860/publications.pdf>

Version: 2024-02-01

22  
papers

2,272  
citations

759055

12  
h-index

713332

21  
g-index

23  
all docs

23  
docs citations

23  
times ranked

3131  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. <i>New England Journal of Medicine</i> , 2017, 377, 1723-1732.	13.9	1,533
2	Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping. <i>JAMA Neurology</i> , 2020, 77, 982.	4.5	169
3	<i>EPG5</i>-related Vici syndrome: a paradigm of neurodevelopmental disorders with defective autophagy. <i>Brain</i> , 2016, 139, 765-781.	3.7	99
4	Comparative Proteomes of the Proliferating C2C12 Myoblasts and Fully Differentiated Myotubes Reveal the Complexity of the Skeletal Muscle Differentiation Program. <i>Molecular and Cellular Proteomics</i> , 2004, 3, 1065-1082.	2.5	75
5	Mouse Survival Motor Neuron Alleles That Mimic SMN2 Splicing and Are Inducible Rescue Embryonic Lethality Early in Development but Not Late. <i>PLoS ONE</i> , 2010, 5, e15887.	1.1	71
6	Paraffin-wax-coated plates as matrix-assisted laser desorption/ionization sample support for high-throughput identification of proteins by peptide mass fingerprinting. <i>Analytical Biochemistry</i> , 2004, 327, 222-232.	1.1	61
7	The care of patients with Duchenne, Becker, and other muscular dystrophies in the <scp>COVID</scp>â€19 pandemic. <i>Muscle and Nerve</i> , 2020, 62, 41-45.	1.0	54
8	Combination molecular therapies for type 1 spinal muscular atrophy. <i>Muscle and Nerve</i> , 2020, 62, 550-554.	1.0	51
9	Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, S3-S16.	0.5	34
10	Spinal muscular atrophy care in the COVIDâ€19 pandemic era. <i>Muscle and Nerve</i> , 2020, 62, 46-49.	1.0	31
11	Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy. <i>Journal of Neuromuscular Diseases</i> , 2022, 9, 493-501.	1.1	31
12	An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 810-818.	1.7	18
13	Symptomatic Cerebral Vasospasm Following Resection of a Medulloblastoma in a Child. <i>Neurocritical Care</i> , 2013, 18, 84-88.	1.2	12
14	PIGQ glycosylphosphatidylinositolâ€anchored protein deficiency: Characterizing the phenotype. <i>American Journal of Medical Genetics, Part A</i> , 2019, 179, 1270-1275.	0.7	11
15	Guidelines for Corticosteroid use in Treatment of DMD. <i>Pediatric Neurology Briefs</i> , 2016, 30, 21.	0.2	6
16	Delay in Diagnosis of Duchenne Muscular Dystrophy. <i>Pediatric Neurology Briefs</i> , 2015, 29, 5.	0.2	4
17	Friedreichâ€™s Ataxia: Clinical Presentation of a Compound Heterozygote Child with a Rare Nonsense Mutation and Comparison with Previously Published Cases. <i>Case Reports in Neurological Medicine</i> , 2018, 2018, 1-5.	0.3	2
18	Transforaminal Intrathecal Access for Injection of Nusinersen in Adult and Pediatric Patients with Spinal Muscular Atrophy. <i>Journal of Pediatric Neurology</i> , 2020, 18, 088-094.	0.0	2

#	ARTICLE	IF	CITATIONS
19	Spinal Muscular Atrophy Diagnosed by Newborn Screening. <i>Pediatric Neurology Briefs</i> , 2019, 33, 5.	0.2	2
20	Utility of Repetitive Nerve Stimulation in Myopathies. <i>Pediatric Neurology Briefs</i> , 2020, 34, 4.	0.2	1
21	Palliative Care in Duchenne Muscular Dystrophy: Goals of Care Discussions and Beyond. <i>Muscle and Nerve</i> , 2022, , .	1.0	1
22	Orofacial EMG in Congenital Multiple Cranial Neuropathies. <i>Pediatric Neurology Briefs</i> , 2015, 29, 68.	0.2	0